Lexaria
Strengthens
its International
Patent Portfolio to 19 Patents Granted
New
patent
granted
in
India bolsters
worldwide patent coverage,
adding
to
existing patents in
the EU,
the U.S.,
and
Australia
Kelowna,
British Columbia,
May
12,
2021
-- InvestorsHub NewsWire -- Lexaria Bioscience Corp.
(Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the "Company" or
"Lexaria"), a global innovator in drug
delivery
platforms, announces further expansion of its intellectual
property portfolio with its first-ever patent granted in
India.
The patent is titled
"Stable
ready-to-drink beverage compositions comprising lipophilic active
agents"
and is of particular
importance given the size of the Indian
population, which is nearly four times as large as the U.S.
population.
The patent is
valid for 20 years from the patent application date of Dec. 1,
2016.
"This is our
19th
patent granted
worldwide, allowing us to innovate in the ready-to-drink beverage
composition category around the world," said Chris Bunka, CEO
of Lexaria. "This new patent
complements our existing suite of granted patents spanning
the EU,
the U.S.,
and
Australia, and provides intellectual
property protection to both consumer-packaged goods as well as
registered drug applications. We believe these are robust growth
categories that add to Lexaria's strategic
value."
This is the
second
patent granted
from Lexaria's third patent
family. Lexaria's patent application suite has
grown to a total of 13 patent families.
Active ingredients
that may be used under this new patent include NSAIDS
(e.g., acetylsalicylic acid, ibuprofen, diclofenac, indomethacin,
piroxicam), fat-soluble
vitamins,
and
acetaminophen.
Active ingredients
under
the new patent also
include nicotine
and cannabinoids.
Claims granted cover a wide range of product
formats,
including non-carbonated
beverages, carbonated beverages, colas, root beers, fruit-flavoured
beverages, citrus-flavored
beverages,
fruit juices, fruit-containing
beverages, vegetable juices, vegetable-containing
beverages, teas, coffees,
dairy beverages, protein-containing
beverages, shakes, sports drinks, energy drinks, and
flavored
waters.
Lexaria
has
patent applications progressing in countries around the world with
aggregate populations of approximately 3.7 billion people and will
report on further progress as information becomes
available.
About
Lexaria
Bioscience
Corp.
Lexaria Bioscience Corp.'s
proprietary drug delivery technology, DehydraTECH™,
improves the way active pharmaceutical ingredients (APIs) enter the
bloodstream by promoting healthier oral ingestion methods and
increasing the effectiveness of fat-soluble active molecules,
thereby lowering overall dosing. The Company's technology can be
applied to many different ingestible product formats, including
foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH
has repeatedly
demonstrated since 2016 with cannabinoids and nicotine the ability
to increase bio-absorption by up to 5-10x, reduce time of
onset from
1-2 hours to minutes, and mask
unwanted tastes. DehydraTECH
is planned to be
further evaluated for orally administered bioactive molecules,
including anti-virals, cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), and
nicotine. Lexaria has licensed
DehydraTECH
to multiple
companies, including a world-leading
tobacco producer for the development of smokeless, oral-based
nicotine products, and for use in industries
that produce cannabinoid beverages, edibles, and oral
products. Lexaria operates a licensed in-house
research laboratory and holds a robust intellectual property
portfolio with 19 patents granted and
approximately 60 patents pending worldwide. For more information,
please visit
www.lexariabioscience.com.
CAUTION
REGARDING FORWARD-LOOKING
STATEMENTS
This press release
includes forward-looking statements. Statements as such term is
defined under applicable securities laws. These statements may be
identified by words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions. Such forward-looking statements in
this press release include, but are not limited to, statements by
the Company relating the Company's ability
to carry out research initiatives, receive regulatory approvals or
grants, or experience positive effects
or results from any research or study. Such forward-looking
statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and
uncertainties, and there can be no assurance that the Company will
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements. As such, you should not place
undue reliance on these forward-looking statements.
Factors which
could cause actual results to differ materially from those
estimated by the Company include, but are not limited to,
government regulation and regulatory approvals, managing and
maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and
approval process, potential adverse effects arising from the
testing or use of products utilizing the DehydraTECH
technology, the
Company's ability to maintain existing collaborations and realize
the benefits thereof, delays or cancellations of
planned R&D that could occur related to pandemics or for other
reasons, and other factors which may be
identified from time to time in the Company's public announcements
and periodic filings with the U.S. Securities and Exchange
Commission on EDGAR. There is no assurance that any of
Lexaria's
postulated uses,
benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug
Administration (FDA). Lexaria-associated products are not
intended to diagnose, treat, cure, or prevent any
disease. Any forward-looking statements
contained in this release speak only as of the date hereof, and the
Company expressly disclaims any obligation to update any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed
circumstances, or otherwise, except as
otherwise required by law.
The CSE
has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
INVESTOR
CONTACT:
ir@lexariabioscience.com
Phone:
866-221-3341